MedTrace Logo

Good-first: B/F/TAF As First-line ART

NCT06619288 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 630

Last updated 2024-10-01

No results posted yet for this study

Summary

This is a multicohort study conducted at Affiliated Hospital of Nantong University, and Nantong Third Peoples Hospital (Designated Hospital for HIV/AIDS Treatment of Nantong City), China. The study would involve 630 patients initiating HIV treatment, divided into six cohorts. The enrollment period for the prospective cohort is from July 2024 to June 2025, while the enrollment period for the retrospective cohort is from January 2020 to June 2023.

Conditions

  • HIV Infection

Interventions

DRUG

B/F/TAF

Take one tablet per dose, once daily. Each tablet contains bictegravir (BIC) 50 mg, emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 25 mg.

DRUG

TDF+3TC+EFV

Take five tablets per dose, once daily. Each dose contains one tablet of tenofovir (TDF) 300 mg, one tablet of lamivudine (3TC) 300 mg, and three tablets of efavirenz (EFV) 200 mg (totaling 600 mg).

DRUG

DTG/3TC

Take one tablet per dose, once daily. Each tablet contains dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg.

Sponsors & Collaborators

  • Nantong Third Peoples Hospital

    collaborator UNKNOWN

  • Affiliated Hospital of Nantong University

    lead OTHER

Principal Investigators

  • Gang Qin, MD, PhD · Affiliated Hospital of Nantong University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2025-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06619288 on ClinicalTrials.gov